Cefepime
It is a prototypic agent of new class of fourth generation cephalosporins which offers more stability against beta-lactamases and greater penetration in bacteral cell wall. As it has high affinity for penicillin binding proteins, it exerts antimicrobial effect by attaching to them & disrupting the cell wall synthesis.Gynecological and moderate to severe intra abdominal infections post surgery, in acute pelvic infections, bacteremia, septicaemia, lower respiratory tract infection, severe pneumonia, febrile neutropenia, acute leukemia, urinary tract infections (UTI).
In Moderate to Severe Pneumonia: for paediatrics : 50mg/kg/dose IV for 12 hours for 10 days and for adults : 1 to 2 gm IV for 12 hours for 10 days. In Febrile Neutropenia : For paediatric dose 50mg/kg/dose and for adults 2g IV respectively every 8 hours continue for 7 days/resolution of Neutropenia. Urinary Tract Infection : For paediatrics dose 50mg/kg/dose IV every 12 hours for 7 to 10 days and for adult 0.5g to 1g IV and every 12 hours for 7 to 10 days. In Skin and Skin structure infection
Contraindicated in patients having a history of allergy to cephalosporins
Hypersensitivity to penicillins or other ß-lactam antibiotics. Patient w/ history of seizure disorder, history of GI disease, particularly colitis. Renal impairment. Pregnancy and lactation.
Anaphylaxis, pruritus, rash fever
No clinical significant interaction have been reported
